Showing 4,061 - 4,080 results of 11,397 for search 'significantly ((((lower decrease) OR (((we decrease) OR (mean decrease))))) OR (linear decrease))', query time: 0.45s Refine Results
  1. 4061

    SPIRIT Schedule of Enrollment. by Asma Salari (21432948)

    Published 2025
    “…</p><p>Results</p><p>The EX group showed increased EMG activation for the tibialis anterior, gastrocnemius medialis, rectus femoris, and biceps femoris in both anterior-posterior (2.23 MVIC%, 95% CI: 1.13 to 3.34, p < 0.001) and posterior-anterior directions (2.35 MVIC%, 95% CI: 1.80 to 2.91, p < 0.001) compared to CO group. Onset time decreased significantly in the EX group relative to CO group (anterior-posterior: -108.07 ms, 95% CI: -117.23 to -98.89, p < 0.001; posterior-anterior: -98.72 ms, 95% CI: -106.54 to -90.90, p < 0.001). …”
  2. 4062

    Measuring muscle strength [49]. by Asma Salari (21432948)

    Published 2025
    “…</p><p>Results</p><p>The EX group showed increased EMG activation for the tibialis anterior, gastrocnemius medialis, rectus femoris, and biceps femoris in both anterior-posterior (2.23 MVIC%, 95% CI: 1.13 to 3.34, p < 0.001) and posterior-anterior directions (2.35 MVIC%, 95% CI: 1.80 to 2.91, p < 0.001) compared to CO group. Onset time decreased significantly in the EX group relative to CO group (anterior-posterior: -108.07 ms, 95% CI: -117.23 to -98.89, p < 0.001; posterior-anterior: -98.72 ms, 95% CI: -106.54 to -90.90, p < 0.001). …”
  3. 4063

    Details of aquatic exercise protocol. by Asma Salari (21432948)

    Published 2025
    “…</p><p>Results</p><p>The EX group showed increased EMG activation for the tibialis anterior, gastrocnemius medialis, rectus femoris, and biceps femoris in both anterior-posterior (2.23 MVIC%, 95% CI: 1.13 to 3.34, p < 0.001) and posterior-anterior directions (2.35 MVIC%, 95% CI: 1.80 to 2.91, p < 0.001) compared to CO group. Onset time decreased significantly in the EX group relative to CO group (anterior-posterior: -108.07 ms, 95% CI: -117.23 to -98.89, p < 0.001; posterior-anterior: -98.72 ms, 95% CI: -106.54 to -90.90, p < 0.001). …”
  4. 4064

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  5. 4065

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  6. 4066

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  7. 4067

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  8. 4068

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  9. 4069
  10. 4070

    Prediction of transition readiness. by Sharon Barak (4803966)

    Published 2025
    “…In most transition domains, help needed did not decrease with age and was not affected by function. …”
  11. 4071
  12. 4072

    Baseline analysis, nominal factors. by Hiroaki Yoshikawa (4615801)

    Published 2025
    “…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
  13. 4073

    Minimal dataset for the study. by Hiroaki Yoshikawa (4615801)

    Published 2025
    “…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
  14. 4074

    Baseline analysis, continuous factors. by Hiroaki Yoshikawa (4615801)

    Published 2025
    “…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
  15. 4075

    Multivariable analysis between 2006 and 2018. by Hiroaki Yoshikawa (4615801)

    Published 2025
    “…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
  16. 4076

    OVX educes bone density of femur. by Mingzhu Chen (6370013)

    Published 2025
    “…Compared to Sham rats, OVX tats had a significant decrease in bone mass and impaired bone micro structure: (L) BMD, (M) BV, (N) BV/TV, (O) Tb.N,(P) Tb.Sp, and (Q) Tb.Th. …”
  17. 4077
  18. 4078

    <b> </b> Energy efficiency and gas volume comparison. by Ning Zuo (17295415)

    Published 2025
    “…CO₂ yield was higher in the control group at lower temperatures, while the integrated system consistently produced more biochar and biogas. …”
  19. 4079

    Model validation of kinetic parameters. by Ning Zuo (17295415)

    Published 2025
    “…CO₂ yield was higher in the control group at lower temperatures, while the integrated system consistently produced more biochar and biogas. …”
  20. 4080

    A Hydrate-Bearing Sediment Gas Replacement Mechanical Behavior Regulation Mechanism and Slope Stability Analysis by Lei Huang (35191)

    Published 2025
    “…The Ψ value on the <i>v</i>-ln <i>p</i>′ plane is consistently negative, and gas replacement results in higher ln <i>p</i>′ values and lower <i>v</i> at the failure state point. As saturation increases, the Γ value of the critical state line decreases, while the λ value increases. (3) For slope simulations, increased hydrate saturation significantly raises the safety factor for gentler slopes, while the reinforcing effect of gas replacement is weaker for steeper slopes with higher saturation.…”